logo apx for dark background

Investments

First proof-of-concept partner signed

ZURICH 18 DECEMBER 2022. Apricot Therapeutics signed its first proof-of-concept partnership agreement to generate a unique dataset for the characterization of novel compounds that target previously thought undruggable proteins involved in cancer.